Form 4: Bicara Therapeutics CEO Granted 450,000 Stock Options

Bicara Therapeutics CEO Claire Mazumdar received a grant of 450,000 stock options with an exercise price of $16.76, vesting quarterly over four years.

Summary

• Claire Mazumdar, Chief Executive Officer and Director of Bicara Therapeutics Inc. (BCAX), was granted 450,000 stock options.
• The stock options have an exercise price of $16.76 per share.
• The transaction date for this grant was February 2, 2026.
• The options vest in sixteen equal quarterly installments following February 2, 2026, contingent on Ms. Mazumdar's continued service.
• The expiration date for these stock options is February 2, 2036.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive event, as it represents a standard executive compensation practice that aligns management incentives with shareholder value, without indicating any immediate operational or financial changes.

Positives

• The grant of 450,000 stock options aligns the Chief Executive Officer's long-term incentives with shareholder interests, promoting sustained performance.
• The vesting schedule over sixteen equal quarterly installments encourages long-term commitment and retention of key management.

Future Outlook

The vesting schedule of the stock options, extending over four years, indicates an expectation of continued service from the Chief Executive Officer and a long-term commitment to the company's performance.

Industry Context

StockSavvy.ai notes that the grant of stock options to a Chief Executive Officer is a common practice in the biotechnology industry, designed to incentivize leadership through equity participation and align their financial interests with the company's long-term success and shareholder value creation. The exercise price of $16.76 reflects the stock's value at the time of the grant.

Stakeholder Impact

• Shareholders: The grant of stock options to the CEO aims to align her interests with those of shareholders, potentially leading to increased focus on long-term stock performance.
• Employees: The CEO's long-term incentive structure may indirectly influence overall company strategy and employee morale.

Next Steps

• The stock options will vest in sixteen equal quarterly installments following February 2, 2026, subject to the Reporting Person's continued service.

Key Dates

Keywords

Bicara Therapeutics, BCAX, Stock Options, Executive Compensation, Insider Transaction, Claire Mazumdar, CEO, Form 4